Cornerstone Therapeutics, Targacept deal

Cornerstone granted Targacept exclusive, worldwide rights to its nicotinic receptor patents and preclinical

Read the full 130 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE